Dasatinib inhibits the proliferation and function of CD4+CD25+regulatory T cells-Reference-Cited by-同舟云学术

Dasatinib inhibits the proliferation and function of CD4+CD25+regulatory T cells

Published:2009-01 Issue:2 Volume:144 Page:195-205
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Fei Fei,Yu Yingzhe,Schmitt Anita,Rojewski Markus Thomas,Chen Baoan,Götz Marlies,Döhner Hartmut,Bunjes Donald,Schmitt Michael

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2008.07433.x/fullpdf

Reference42 articles.

1. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine;Beyer;Blood,2005

2. The receptor for hyaluronic acid-mediated motility induces specific CD8+ T cell response in healthy donors and patients with chronic myeloid leukemia after allogeneic stem cell transplantation;Chen;International Journal of Oncology,2007

3. Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro;Chen;Cancer Immunology, Immunotherapy,2007

4. Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner;Chen;International Journal of Oncology,2007

5. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis;Cortes;Blood,2007

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Significance of Regulatory T-Cells and PD-1 + CD8 T-Cells in Chronic Myeloid Leukemia Patients Treated with Generic Imatinib;Indian Journal of Hematology and Blood Transfusion;2024-08-20

2. A lower initial dose of bosutinib for patients with chronic myeloid leukemia patients resistant and/or intolerant to prior therapy: a single-arm, multicenter, phase 2 trial (BOGI trial);International Journal of Hematology;2024-08-13

3. Dasatinib, a selective tyrosine kinase inhibitor, prevents joint destruction in rheumatoid arthritis animal model;International Journal of Rheumatic Diseases;2023-02-21

4. Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia;Haematologica;2023-01-26

5. Cytomegalovirus US28 regulates cellular EphA2 to maintain viral latency;Science Advances;2022-10-28